New recombinant antibodies launched!

Menu Search
PRODUCT CODE: EM1901-33

Cytokeratin 14 Monoclonal Antibody (EM1901-33)

  • IVD–IHC

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

-
+
Cart0
Western blot analysis of Cytokeratin 14 on A431 lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Western blot analysis of Cytokeratin 14 on A431 lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.
  • Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-Cytokeratin 14 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (, 1/200) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Immunohistochemical analysis of paraffin-embedded human skin tissue using anti-Cytokeratin 14 antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 8.0-8.4) for 20 minutes.The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (, 1/200) for 30 minutes at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Flow cytometric analysis of Cytokeratin 14 was done on A431 cells. The cells were fixed, permeabilized and stained with the primary antibody (, 1/100) (red). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated goat anti-Mouse IgG Secondary antibody at 1/500 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; black).
Western blot analysis of Cytokeratin 14 on A431 lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (, 1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Mouse IgG - HRP Secondary Antibody (HA1006) at 1:5,000 dilution was used for 1 hour at room temperature.

Applications

  • WB

  • IHC-P

  • FC

REACTIVITY

  • Human

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

Cytokeratin 14 Monoclonal Antibody (EM1901-33)

Immunogen

Synthetic peptide within n-terminal human cytokeratin 14.

Host

Mouse

Positive Control

A431 cell lysates, human tonsil tissue, human skin tissue.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

A2C10

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein G purified.

MOLECULAR WEIGHT

51 kDa

Isotype

IgG1

APPLICATION DILUTION

  • WB

  • 1:500-1:2,000

  • IHC-P

  • 1:50-1:200

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

P02533

PROTEIN NAME

Cytokeratin 14

SYNONYMS

CK 14 antibody; CK-14 antibody; ck14 antibody; Cytokeratin 14 antibody; Cytokeratin-14 antibody; Cytokeratin14 antibody; Dowling Meara antibody; EBS3 antibody; EBS4 antibody; Epidermolysis bullosa simplex antibody; K14 antibody; K1C14_HUMAN antibody; Keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, Koebner) antibody; Keratin 14 antibody; Keratin antibody; Keratin type I cytoskeletal 14 antibody; Keratin, type I cytoskeletal 14 antibody; Keratin-14 antibody; Keratin14 antibody; Koebner antibody; Krt 14 antibody; Krt14 antibody; NFJ antibody; OTTHUMP00000164624 antibody; type I cytoskeletal 14 antibody

SEQUENCE SIMILARITIES

Belongs to the intermediate filament family.

TISSUE SPECIFICITY

Expressed in the corneal epithelium (at protein level). Detected in the basal layer, lowered within the more apically located layers specifically in the stratum spinosum, stratum granulosum but is not detected in stratum corneum. Strongly expressed in the outer root sheath of anagen follicles but not in the germinative matrix, inner root sheath or hair. Found in keratinocytes surrounding the club hair during telogen.

POST-TRANSLATIONAL MODIFICATION

A disulfide bond is formed between rather than within filaments and promotes the formation of a keratin filament cage around the nucleus.; Ubiquitinated by the BCR(KLHL24) E3 ubiquitin ligase complex.

SUBCELLULAR LOCATION

Cytoplasm, Nucleus.

FUNCTION

Keratin 14 is a member of the type I keratin family of intermediate filament proteins. Keratin 14 is also known as cytokeratin-14 (CK-14) or keratin-14 (KRT14). In humans it is encoded by the KRT14 gene. Keratin 14 is usually found as a heterodimer with type II keratin 5 and form the cytoskeleton of epithelial cells. Cytokeratin 14 is found in squamous epithelial basal cells, myoepithelium, some glandular epithelia, and mesothelial cells. Anti-Cytokeratin 14 is useful for distinguishing squamous cell carcinomas from other epithelial tumors, and for classifying metaplastic breast carcinomas. The Cytokeratin 14 (IHC555) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. Use of this antibody is indicated, subsequent to clinical differential diagnoses of diseases, as an aid in the identification of squamous cell carcinomas within the context of antibody panels, the patient’s clinical history and other diagnostic tests evaluated by a qualified pathologist.